Drug intelligence / Profile preview

ketotifen + vasoconstrictor

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Ophthalmic, Topical
01

Overview

This is a **combination drug** composed of **ketotifen**, a mast cell stabilizer and H1-antihistamine, and a **vasoconstrictor** (component unspecified, as "vasoconstrictor" is a pharmacological action and could refer to any of several agents). Ketotifen works by inhibiting the release of histamine and other mediators from mast cells, providing anti-allergic and anti-inflammatory effects, and blocks H1 histamine receptors, reducing symptoms like itching, swelling, and wheezing[2]. Vasoconstrictors generally act by constricting blood vessels, reducing blood flow, and are commonly used in ophthalmic, nasal, or local anesthetic products. The combination would provide both mast cell stabilization and reduced vascular permeability/bleeding; however, the precise mechanism and safety profile will depend on the specific vasoconstrictor used. In vascular physiology studies, ketotifen altered the vasoconstrictor response in arteries, acting mainly by reducing neuronal nitric oxide release and histamine-mediated responses[1].

02

Targets

NOS1 (nNOS)PGD (6-Phosphogluconate dehydrogenase)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on ketotifen + vasoconstrictor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketotifen + vasoconstrictor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call